



4 September 2023

ReNeuron Group plc
(“ReNeuron”, the “Company” or the “Group”)

R&D Update
Creating a valuable and differentiated Exosome Delivery Platform

ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that it has successfully generated *in vivo* data to exemplify the cellular and tissue targeting capabilities of exosomes produced from its multiple conditionally immortalised producer cell lines. The Company will now look to broaden its capabilities and focus on the functional delivery of specific payloads.

Randolph Corteling, Chief Scientific Officer, commented: *“I am pleased to confirm that over the last six months we have generated comparative in vivo data demonstrating distinct organ and cellular targeting capabilities of our proprietary stem-cell derived exosomes, which differentiates our CustomEX™ platform from that of our competitors.”*

Iain Ross, Executive Chairman, said: *“On the basis of this data the Company will now look to broaden its capabilities and, in liaison with partners and collaborators, focus on the functional delivery of specific payloads. We look forward to updating shareholders in due course.”*

Enquiries:

ReNeuron

Iain Ross, Executive Chairman
John Hawkins, Chief Financial Officer

www.reneuron.com/investors

Via Walbrook PR

Allenby Capital Limited (Nominated Adviser and Broker)

James Reeve/George Payne (Corporate Finance)
Stefano Aquilino/Kelly Gardiner (Sales & Corporate Broking)

+44 (0)20 3328 5656

Walbrook PR (Media & Investor Relations)

Paul McManus / Alice Woodings

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7407 804 654

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as “should”, “expects”, “estimates”, “believes” or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the

growth of markets and demand for products. By their nature, forward-looking also statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.